輔大醫院8月開!挖走台大33名醫 醫界震撼:不要再挖啦 生活中心/綜合報導輔大醫院八月將營運,卻先在醫界投下震撼彈!
Pages
Friday, March 3, 2017
台大心臟外科名醫 王水深(準輔大醫院院長): 台大不會倒
富士康 (郭台銘) 替 華大基因 檢測儀 出貨 (10萬台 起跳) !!!
鴻海攜華大基因 強攻醫療 2017-03-03 03:21:39 經濟日報 記者尹慧中/台北報導鴻海集團擴大八大生活領域的健康布局。
台灣 罕病立法保護 (全球TOP 5): 公告215種病/ 98種藥/ 40項特殊營養品
國際罕見疾病日 國健署:鼓勵研發 2017-02-27 匯流新聞網記者/王少筠綜合報導 每年2月的最後一天為「國際罕見疾病日(Rare Disease Day)」,由「歐洲罕見疾病組織(EURORDIS)」於20
Roche羅氏 Perjeta+Herceptin成功用於乳癌手術切除使用 (post surgery): Perjeta營收估41.6億 (2022年)
羅氏藥廠乳癌用藥 試驗成功 2017-03-02 18:03經濟日報 記者謝汶均╱即時報導 羅氏藥廠(Roche)乳癌用藥Perjeta成功完成臨床試驗
Roche's Perjeta chalks up needed win in Herceptin combo trial, but questions remain by Tracy Staton | Mar 2, 2017 11:27am Perjeta's top-line victory in a new trial suggests it might nab sales growth in a new group of patients, but until full details are available, "some degree of hand-wringing will likely continue, in terms of just how big the clinical benefit is likely to be," Bernstein analyst Tim Anderson said. Roche got its hoped-for win in a crucial breast cancer trial—at least in principle. The question is how big that win might be. The Swiss-based drugmaker said Thursday that its next-gen HER2-positive cancer therapy, Perjeta, staved off cancer progression in patients at an early stage of the disease whose tumors had been surgically removed. The announcement didn't include detailed data—those will be presented at a cancer meeting this year—but the bare fact of success suggests that a new FDA-approved use could be on the way for the Roche med. The adjuvant trial, dubbed Aphinity, tested Perjeta alongside Herceptin, its gold standard treatment for HER2-positive breast cancer, and chemotherapy. The cocktail is already approved to treat metastatic breast cancer and early-stage disease before surgery, and the after-surgery treatment setting would be a sizable new market for Perjeta to tackle. That would be a welcome development for Roche as its top-selling drugs get ever closer to biosimilar competition. Herceptin's turn could come as early as next year, some analysts say, with patent expiration set for 2019. That doesn't give Roche much time to amp up sales of its other drugs to help absorb the blow—and a new Perjeta indication is one prospect investors have been watching very closely. Compared with patients on Herceptin and chemo alone, patients in the Perjeta combo arm saw a "statistically significant reduction in the risk of recurrence of invasive disease or death," Roche said in a release. The company says it will be taking the data to the FDA and European regulators. Bernstein analyst Tim Anderson said Thursday that the will-it-or-won't-it question on Aphinity has been making Roche investors nervous, despite indications from previous trials that the Perjeta combo would work. The fact that it did, in fact, work is likely to be a boost for Perjeta and could be a stabilizer for Herceptin down the road. The Perjeta combo uses have given Herceptin some help already, as the older drug is used for a longer time period in those indications. And importantly, the trial turned up no new safety signals for the combo. But Anderson figures that the new indication, if approved, won't be an overwhelming driver of new sales."We have viewed the magnitude of the benefit as likely to be modest because Herceptin works pretty well," Anderson wrote in a Thursday note, "yet good safety/tolerability would still drive meaningful sales growth." And until the specifics on the Aphinity results are presented—likely at the American Society of Clinical Oncology meeting in June—it's unclear just how much the new data would change clinical practice. A breast cancer specialist told Bernstein analysts last year that the combo will need to deliver at least a 2% to 3% improvement over Herceptin and chemo alone."Without full details of the data … some degree of hand-wringing will likely continue, in terms of just how big the clinical benefit is likely to be," Anderson noted. His firm now estimates that Perjeta sales would peak in 2022 at about 4.2 billion Swiss francs, or $4.16 billion, up from 1.85 billion francs last year (which itself marked 26% growth). For comparison's sake, Herceptin brought in 6.78 billion francs in 2016. Meanwhile, Herceptin biosims are marching forward. Mylan and Biocon have a Herceptin biosim under FDA review right now, Pfizer's knockoff recently succeeded in a key trial, and Amgen and Allergan together have a version progressing toward the market.
Pertuzumab (Perjeta®) 2012, 十月 7 - 11:21 資料來源:新光藥訊(第119期) 記者:黃士蓉、柯榮川 一、前言 乳癌是女性最常見的癌症,每年全球約有140萬的乳癌新病例且超
川普要求FDA加快新藥核准 藥界CEO不樂見 !
NBI生技躍14月高!川普讚孤兒藥 藥價政策不致太苛? 2017/03/02 10:03 MoneyDJ新聞 2017-03-02 10:03:59 記者 郭妍希 報導 美國藥品定價過高、新藥核准程序冗長繁瑣,一直為人詬病。
Amicus CEO John Crowley, Not His Daughter Megan, Might Compel Trump to Make Big Changes at FDA by Adam Feuerstein Mar 1, 2017 8:12 AM EST Absent specific policy details, Trump's speech leaves investors guessing about his real plans for the FDA and the drug approval process. He has not yet named an FDA commissioner. In his speech to Congress Tuesday night, President Donald Trump called the FDA drug approval process "slow and burdensome." To support his argument, Trump pointed to Megan Crowley, a 20-year-old Pompe disease patient. Crowley was in the gallery of the House chamber listening to Trump's speech.
Here's what Trump said: An incredible young woman is with us this evening who should serve as an inspiration to us all. Today is Rare Disease day, and joining us in the gallery is a Rare Disease Survivor, Megan Crowley. Megan was diagnosed with Pompe Disease, a rare and serious illness, when she was 15 months old. She was not expected to live past 5. On receiving this news, Megan's dad, John, fought with everything he had to save the life of his precious child. He founded a company to look for a cure, and helped develop the drug that saved Megan's life. Today she is 20 years old -- and a sophomore at Notre Dame. Megan's story is about the unbounded power of a father's love for a daughter. But our slow and burdensome approval process at the Food and Drug Administration keeps too many advances, like the one that saved Megan's life, from reaching those in need. If we slash the restraints, not just at the FDA but across our Government, then we will be blessed with far more miracles like Megan. In fact, our children will grow up in a Nation of miracles. Trump has previously expressed a desire to deregulate the FDA and lower the standards by which drugs are approved in the U.S. His comments about Megan Crowley seem to fit that theme. But you could also argue Megan Crowley is an example of an FDA system that works well to quickly address the needs of patients suffering from rare diseases. Crowley's life was saved by Myozyme, an enzyme replacement therapy developed Genzyme, now a part of Sanofi (SNY). Megan's father, John Crowley, formed a small company to develop Pompe disease drugs that was acquired by Genzyme and contributed to the successful development of Myozyme. Myozyme was studied in two, uncontrolled clinical trials that enrolled a total of 39 Pompe disease patients. Genzyme submitted the Myozyme clinical data package to the FDA in July 2005. The FDA reviewed the drug's clinical data and approved it in April 2006 -- nine months later.
That hardly seems slow or burdensome. The FDA has not been as kind to Amicus Therapeutics (FOLD) , the small orphan drug company run by John Crowley, Megan's father. John Crowley started Amicus after helping to develop Myozyme. Last November, the FDA refused Amicus' request to submit an accelerated approval filing for Galafold, a new therapy to treat Fabry disease. The FDA told Amicus that an additional clinical study of Galafold would be required before the drug could be submitted and reviewed. Amicus estimates collecting the new data will take two years. In contrast, European drug regulators approved Galafold in May 2016 using the same clinical data FDA deemed insufficient. Amicus is selling Galafold to Fabry patients in Europe but can't do the same in the U.S. Critics of the current FDA approval process could point legitimately to John Crowley and Amicus -- more than his daughter Megan -- to support their argument for less regulation. FDA supporters will counter that the agency's decision to turn away Galafold for more data did not harm Fabry patients in the U.S. or deny them treatment because Fabrazyme, an enzyme replacement therapy from Sanofi, is approved here and used to treat Fabry patients. If Trump's FDA rhetoric becomes reality, Amicus might benefit. Will the rest of the biotech industry? Lowering approval standards at FDA is not something most biotech and drug industry executives want to see happen.
(白化症 眼睛病變/震顫) 北市聯合醫 林育葳: 視力成熟期5~7歲 把握3歲前治療
「月亮孩子」的苦你知道嗎?醫:白化症應納罕病 2017/03/02記者楊晴雯/台北報導一位居住在金門的5歲
亞獅康&莊偉裕教授 開發dihydroorotate dehydrogenase (DHODH) 抑制劑(ASLAN003) 治療AML
亞獅康攜手星國學術機構,合作研究ASLAN003抗癌療法 MoneyDJ新聞 2017-03-02 10:16:57 記者 新聞中心 報導專注免疫療法與標靶抗癌藥物開發之生技公司亞獅康-KY(
A new target for differentiation therapy in AML Cell Research (2017) 27:9–10. doi:10.1038/cr.2016.130; published online 11 November 2016 Despite major advances in understanding the genetics and epigenetics of acute myelogenous leukemia, there is still a great need to develop more specific and effective therapies. High throughput approaches involving either genetic approaches or small molecule inhibitor screens are beginning to identify promising new therapeutic targets. One approach to develop new acute myelogenous leukemia (AML) therapies has been to design mechanism-based inhibitors. This has led to a number of new therapeutic agents entering clinical trials, including inhibitors of the DOT1L methyltransferase, BRD4 and IDH1/IDH21. This approach requires knowledge of the driver oncogenic mutation and is limited to specific genetic subtypes of AML. A further challenge is that other cooperating oncogenes may confer chemotherapy resistance. An alternative approach is to screen for agents that overcome the block to myeloid differentiation seen in AML. The most notable success was the discovery that trans retinoic acid (ATRA) induces differentiation of promyelocytic cell lines. This has led to the successful use of ATRA for patients with APL. But how can similar agents to overcome differentiation block for the other 90% of AML cases be identified? Sykes et al. recently reported a powerful approach that should be broadly applicable to discovering new differentiation inducers in a wide range of AML cases. The authors noted that the homeobox-containing transcription factor HOXA9 is overexpressed in more than 50% of AML cases, including leukemias with MLL rearrangements, NUP98 translocations, NPM1 mutations and CDX2/CDX4 overexpression. Furthermore, this deregulation is important for leukemogenesis. The authors generated an inducible model of myeloid differentiation arrest by expressing an estrogen receptor-HoxA9 (ER-Hoxa9) fusion protein in murine bone marrow cells. Addition of β-estradiol (E2) to ER-Hoxa9-expressing cells induces the translocation of ER-HoxA into the nucleus thereby blocking myeloid differentiation. These immortalized cells were arrested at the granulocyte-macrophage progenitor (GMP) stage, but undergo synchronous and terminal neutrophil differentiation upon E2 withdrawal. To facilitate the screening of small molecules stimulating myeloid differentiation, Sykes et al. generated a Lys-GFP-ER-HOXA9 cell line with the inducible HOXA9 using knockin mice, in which GFP is inserted into the lysozyme locus. Lysozyme is only expressed in mature granulocytes, so that GFP expression serves as a reporter for screening compounds that induce differentiation. A library of 330 000 molecules was screened and of these, 12 induced myeloid differentiation. The activity of these was further tested in other AML lines and two with distinct chemical scaffolds (C03 and C07) were selected for optimization because of their activity in both murine and human AML cells. Identification of DHODH as a target for differentiation therapy. Myeloid cells were conditionally immortalized by expression of estrogen receptor-HoxA9 (ER-HOXA9) fusion protein in bone marrow cells in which GFP is inserted into the lysozyme locus. Removal of β-estradiol (E2) causes ER-HOXA9 to remain in the cytoplasm resulting in myeloid differentiation and expression of GFP and granulocyte markers such as CD11b. Screening 330 000 compounds led to the identification of small molecules promoting myeloid differentiation. Ultimately the target of the inhibitors was identified as DHODH, a key regulator of pyrimidine biosynthesis. The next challenge was to identify the protein target of the small molecules responsible for differentiating activity. The authors took the approach of growing the mouse and human cell lines for a long period in either C03 or C07 and analyzing the gene profiles of the drug-resistant cells by RNA-Seq. The resistant cells showed remarkably similar expression profiles, with up regulation of only eight shared genes that turned out to be located within a 100 Kb region of the long arm of human chromosome 16 or murine chromosome 8. One of these genes encoded dihydroorotate dehydrogenase (DHODH), a critical enzyme in uridine synthesis that catalyzes the conversion of dihydroorotate to orotate . Intriguingly, in addition to C03 and C07, all but one of the other 12 compounds identified in the small molecule screening were also found to be DHODH inhibitors. These results strongly suggest that DHODH, and its downstream metabolic product uridine, regulate myeloid differentiation. This possibility is further supported by the finding that uridine can rescue the blockage of cell differentiation induced by DHODH inhibitors and that inhibiting orotidine 5′-phosphate decarboxylase, another essential enzyme regulating pyrimidine synthesis, causes a similar block in myeloid differentiation as that induced by the DHODH inhibitors. The authors developed a lead compound ML390, derived from CO7, but it was found to be poorly bioavailable. Instead, for in vivo experiments, the authors chose a potent and selective inhibitor of DHODH, brequinar sodium (BRQ), which had been tested clinically for other tumors, but not leukemia. Encouragingly, BRQ treatment significantly induced myeloid differentiation, delayed the disease development and reduced the burden of leukemia-initiating cells in the various AML mouse models, including human cell line xenografts, patient-derived xenografts, and syngeneic mouse models caused by a variety of genetic alterations. The experimental approach of Sykes et al. is a powerful example of how high throughput strategies can be employed to identify new targets in AML and other malignancies. In particular the results show considerable promise for DHODH inhibitors, which have previously been used for treatment of other cancers, such as melanoma as well as rheumatoid arthritis and multiple sclerosis, for AML therapy. Notably, using a genetic approach, a CRISPR "dropout" screen, Tzelepis et al. found that a variety of AML cell lines are selectively vulnerable to DHODH depletion. While the precise targets affected by DHODH inhibition remain to be identified, since DHODH is required for UDP-GlcNAc formation and DHODH inhibition reduced protein O-linked N-glycosylation in the AML cells, the inhibitor effects may be mediated through reduced glycosylation of proteins regulating differentiation. There is no shortage of candidates involved. Proteins known to be regulated by GlcNAcylation include RNA polymerase II, transcription factors such as c-MYC, and epigenetic regulators such as the Polycomb protein RING1B6. Aside from further delineating this mechanism, it will be important to test how broadly DHODH inhibition is effective given the heterogeneity of human leukemias and also what drugs will be most successful in combination with DHODH inhibition for complete eradication of leukemia.
References Stein EM, Tallman MS. Blood 2016; 127:71–78. Lo-Coco F, Avvisati G, Vignetti M, et al. N Engl J Med 2013; 369:111–121. Sykes DB, Kfoury YS, Mercier FE, et al. Cell 2016; 167:171–186. Collins CT, Hess JL. Oncogene 2016; 35:1090–1098. Tzelepis K, Koike-Yusa H, De Braekeleer E, et al. Cell Rep 2016; 17:1193–1205. Lewis BA, Hanover JA. J Biol Chem 2014; 289:34440–34448.
中國兒童用藥 不合理比例: 12%~32% !!
医保目录新增91个儿童药 儿童药研发仍是短板 2017-03-02 08:02 来源:广州日报 广州日报全媒体记者 涂端玉用量小、风险大、成本高……儿童药生产多年来一直受冷遇。
市场:儿童专用药占比仅1.7% 本报记者留意到,新版目录新增了91个儿童药品品种,
成人药改一改就算儿童药?越来越多公司开始掘金儿童药领域,
(台大論文案) 張正琪: 2016年11月台大高層要她閉嘴 (校長楊泮池/主秘林達德/副校長郭大維/郭明良)
台大論文案 教部:3月中完成複審 更新:2017年03月02日【記者江禹嬋/台北報導】
張正琪:我是代罪羔羊 不過張正琪提到,她是校園政治鬥爭的受害者,是代罪羔羊;
(台大論文案) 論文造假真正負責人都搞不清楚 可能誤信「造假的人」 指控
涉論文造假遭撤職,張正琪:
張正琪批教評會「指鹿為馬,連論文造假的真正負責人都搞不清楚」
確定造假論文,張正琪:僅擔任英文潤飾 在台大教評會所認定「違反學術倫理」的四篇論文,包括JNCI 2006、CDD 2013、Oral Oncol 2013與最嚴重已遭撤搞的JBC 2008,前三篇張正琪都為第一作者,JBC則是第三作者,
張正琪四點聲明如下:第一、 校方105/11/11先要我閉嘴,
美女教授遭解聘 「台大要我閉嘴」2017-03-03〔記者曾韋禎、林曉雲/
圖檔重複已勘誤 也非實驗指導者 張正琪解釋,她只在造假四篇論文中的其中兩篇名列第三作者。二○
台大:調查過程嚴密謹慎 台大則發出聲明反擊,強調所有的調查程序均嚴密謹慎,
(台大論文案) 第三作者 (張正琪) 責任 高於 第一作者/ 權益捍衛戰 !
自由開講》台大論文造假事件 真相只能寄託在張正琪身上 2017-03-03 09:56許文華 台大論文造假事件,非常有技巧的選在二二八連假前一天,也就是2
可待因: 嗎啡 代謝物/ 吃感冒藥 or 吸毒 ?!!
吃感冒藥嗎啡呈陽性?藥師公會:國防部應公布檢驗方式 更新: 2017年03月02日 【記者吳旻洲/台北報導】對於空軍清泉崗基地近日在機坪附近發現
健永 獲 CAROTENOID(類胡蘿蔔素) 醫藥組合物 新加坡專利
健永生技 發言日期106/03/02 發言時間18:14:01 發言人何志煌 發言人職稱事業處總經理 發言人電話02-2732-5205 主旨 公告本公司「類胡蘿蔔素的醫藥組合物 PHARMACEUTICAL COMPOSITIONS OF CAROTENOID」取得 新加坡發明專利 符合條款 第43款 事實發生日106/03/02 說明1.事實發生日:106/03/02 2.公司名稱:健永生技股份有限公司 3.與公司關係(請輸入本公司或聯屬公司):本公司 4.相互持股比例(若前項為本公司,請填不適用):不適用 5.發生緣由:本公司申請之「類胡蘿蔔素的醫藥組合物PHARM
(關聯) 傷口-黨主席選舉-疫苗-台灣歷史
319扁傷口真假?詹啟賢常會說分明 2017-03-01 00:18:14國民黨主席參選人詹啟賢3月1日下午將出席中常
H3N2流感病毒 升溫 (廣華醫院/威爾斯親王醫院/大埔那打素醫院/瑪嘉烈醫院)
流感高峯期殺到 6日奪6命 【本報訊】本港已踏入流感高峯期,衞生防護中心於6天內錄得6宗
生技保健界聯發科 (大江) 董事長(楊武男)退 總經理(林詠翔)接 !
大江生醫董座退休 林詠翔6月接棒 2017-03-02 23:35經濟日報 記者江碩涵╱即時報導 生技界傳出董監事改選消息,據悉,